Education
About Us
Working with TipRanks
Follow Us
Opko Health (OPK)
:OPK
OPK Analyst Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
OPK Stock 12 Month Forecast
Average Price Target
$2.89
▲(129.37% Upside)
| Highest Price Target$5.20 | Average Price Target$2.89 | Lowest Price Target$1.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$1
Hold
-20.63%
Downside
Reiterated
08/03/25
Barrington
$2.25
Buy
78.57%
Upside
Reiterated
08/04/25
H.C. Wainwright
$3
Buy
138.10%
Upside
Reiterated
08/01/25
Opko Health: Strategic Moves and Future Prospects Drive Buy Rating Amid Revenue ChallengesOur 12-month price target is derived from a comparable universe analysis. This primarily employs a spectrum of diagnostics companies contributing to a number of comparative valuation metrics, including an EV/Revenue multiple. Using our projected sales per share for the next 12 months (from 3Q25 to 2Q26) at $0.71 per share, net cash of $0.17 per share (inclusive of $192.5M from the Labcorp transaction), and EV/Revenue ratio of 3.3x, these yield a price objective of roughly $3.
Piper Sandler
$3
Buy
138.10%
Upside
Reiterated
08/01/25
Ladenburg Thalmann & Co.
$5.2
Buy
312.70%
Upside
Initiated
07/08/25
J.P. Morgan
―
Hold
―
Initiated
04/25/25
Jefferies
$2
Buy
58.73%
Upside
Reiterated
03/13/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$1
Hold
-20.63%
Downside
Reiterated
08/03/25
Barrington
$2.25
Buy
78.57%
Upside
Reiterated
08/04/25
H.C. Wainwright
$3
Buy
138.10%
Upside
Reiterated
08/01/25
Opko Health: Strategic Moves and Future Prospects Drive Buy Rating Amid Revenue ChallengesOur 12-month price target is derived from a comparable universe analysis. This primarily employs a spectrum of diagnostics companies contributing to a number of comparative valuation metrics, including an EV/Revenue multiple. Using our projected sales per share for the next 12 months (from 3Q25 to 2Q26) at $0.71 per share, net cash of $0.17 per share (inclusive of $192.5M from the Labcorp transaction), and EV/Revenue ratio of 3.3x, these yield a price objective of roughly $3.
Piper Sandler
$3
Buy
138.10%
Upside
Reiterated
08/01/25
Ladenburg Thalmann & Co.
$5.2
Buy
312.70%
Upside
Initiated
07/08/25
J.P. Morgan
―
Hold
―
Initiated
04/25/25
Jefferies
$2
Buy
58.73%
Upside
Reiterated
03/13/25
Best Analysts Covering Opko Health
1 Month
xxx
Success Rate
11/19 ratings generated profit
Average Return
+1.99%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.89% of your transactions generating a profit, with an average return of +1.99% per trade.
3 Months
xxx
Success Rate
9/19 ratings generated profit
Average Return
+0.72%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 47.37% of your transactions generating a profit, with an average return of +0.72% per trade.
1 Year
Success Rate
13/39 ratings generated profit
Average Return
+7.91%
reiterated a buy rating 3 days ago
Copying Michael Petusky's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +7.91% per trade.
2 Years
xxx
Success Rate
15/39 ratings generated profit
Average Return
+6.92%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 38.46% of your transactions generating a profit, with an average return of +6.92% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
OPK Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
5
7
5
4
4
Buy
3
2
0
0
0
Hold
5
7
6
11
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
16
11
15
14
Each month's total comprises the sum of three months' worth of ratings.
OPK Financial Forecast
OPK Stock Forecast FAQ
What is OPK’s average 12-month price target, according to analysts?
Based on analyst ratings, Opko Health’s 12-month average price target is 2.89.
What is OPK’s upside potential, based on the analysts’ average price target?
Opko Health has 129.37% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is OPK a Buy, Sell or Hold?
Opko Health has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
What is Opko Health’s price target?
The average price target for Opko Health is 2.89. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $5.20 ,the lowest forecast is $1.00. The average price target represents 129.37% Increase from the current price of $1.26.
The highest analyst price target is $5.20 ,the lowest forecast is $1.00. The average price target represents 129.37% Increase from the current price of $1.26.
What do analysts say about Opko Health?
Opko Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of OPK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.